| 0.5434 -0.002 (-0.29%) | 04-25 15:44 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.74  |
1-year : | 0.92 |
| Resists | First : | 0.63 |
Second : | 0.79 |
| Pivot price | 0.56  |
|||
| Supports | First : | 0.38 |
Second : | 0.32 |
| MAs | MA(5) : | 0.53 |
MA(20) : | 0.59 |
| MA(100) : | 0.38 |
MA(250) : | 1.04 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 28 |
D(3) : | 28.1 |
| RSI | RSI(14): 49 |
|||
| 52-week | High : | 3.33 | Low : | 0.12 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ BCLI ] has closed above bottom band by 33.8%. Bollinger Bands are 12.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.56 - 0.56 | 0.56 - 0.56 |
| Low: | 0.51 - 0.51 | 0.51 - 0.51 |
| Close: | 0.54 - 0.54 | 0.54 - 0.55 |
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other neurodegenerative diseases. The company has a partnership with Catalent for manufacturing NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
Tue, 16 Apr 2024
BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of ... - Nasdaq
Thu, 11 Apr 2024
BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule – Company ... - Financial Times
Wed, 10 Apr 2024
BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 ... - PR Newswire
Tue, 09 Apr 2024
BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b ... - Yahoo Finance
Mon, 08 Apr 2024
BrainStorm Cell Therapeutics to Provide Update on NurOwn Program - Yahoo Finance
Mon, 01 Apr 2024
BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 68 (M) |
| Shares Float | 61 (M) |
| Held by Insiders | 12.8 (%) |
| Held by Institutions | 6 (%) |
| Shares Short | 1,340 (K) |
| Shares Short P.Month | 1,070 (K) |
| EPS | -0.41 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.08 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -211.7 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.31 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -20 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -1.34 |
| PEG Ratio | 0 |
| Price to Book value | -6.66 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.78 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|